Department of Biology, Indian Institute of Science Education and Research, Pune, India
Department of Biology, Indian Institute of Science Education and Research, Pune, India.
Genetics. 2019 Mar;211(3):1029-1044. doi: 10.1534/genetics.119.301834. Epub 2019 Jan 22.
Novel genotypes evolve under selection through mutations in pre-existing genes. However, mutations have pleiotropic phenotypic effects that influence the fitness of emerging genotypes in complex ways. The evolution of antimicrobial resistance is mediated by selection of mutations in genes coding for antibiotic-target proteins. Drug-resistance is commonly associated with a fitness cost due to the impact of resistance-conferring mutations on protein function and/or stability. These costs are expected to prohibit the selection of drug-resistant mutations at low drug pressures. Using laboratory evolution of rifampicin resistance in , we show that when exposed intermittently to low concentration (0.1 × minimal inhibitory concentration) of rifampicin, the evolution of canonical drug resistance was indeed unfavorable. Instead, these bacterial populations adapted by evolving into small-colony variants that displayed enhanced pellicle-forming ability. This shift in lifestyle from planktonic to pellicle-like was necessary for enhanced fitness at low drug pressures, and was mediated by the genetic activation of the operon promoter, which allowed expression of type I fimbriae. Upon continued low drug exposure, these bacteria evolved exclusively into high-level drug-resistant strains through mutations at a limited set of loci within the rifampicin-resistance determining region of the gene. We show that our results are explained by mutation-specific epistasis, resulting in differential impact of lifestyle switching on the competitive fitness of different mutations. Thus, lifestyle-alterations that are selected at low selection pressures have the potential to modify the fitness effects of mutations, change the genetic structure, and affect the ultimate fate of evolving populations.
新的基因型通过在现有基因中发生突变而在选择下进化。然而,突变具有表型多效性,以复杂的方式影响新兴基因型的适应性。抗生素耐药性的进化是通过选择编码抗生素靶蛋白的基因突变来介导的。耐药性通常与由于耐药性赋予突变对蛋白质功能和/或稳定性的影响而导致的适应性成本相关。由于耐药性赋予突变对蛋白质功能和/或稳定性的影响,这些成本预计会阻止在低药物压力下选择耐药性突变。通过在 中进行利福平耐药性的实验室进化,我们表明,当间歇性地暴露于低浓度(最小抑菌浓度的 0.1 倍)的利福平时,经典耐药性的进化实际上是不利的。相反,这些细菌种群通过进化为具有增强的生物膜形成能力的小菌落变体来适应。从浮游生物到生物膜样的生活方式的转变对于在低药物压力下提高适应性是必要的,并且是由 操纵子启动子的遗传激活介导的,这允许表达 I 型菌毛。在持续的低药物暴露下,这些细菌通过在 基因的利福平耐药决定区的有限数量的基因座中发生突变,进化为高耐药水平的耐药菌株。我们表明,我们的结果可以通过突变特异性上位性来解释,这导致生活方式转变对不同 突变的竞争适应性产生不同的影响。因此,在低选择压力下选择的生活方式改变有可能改变突变的适应性效应,改变遗传结构,并影响进化种群的最终命运。